Citalopram

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Citalopram

Examples of brand names: Cipramil [DE]

ATC code: N06AB04

Main use (for orientation): Depression

Documented research summary

CBD increases citalopram exposure: controlled study CL11 AUC +43%, Cmax +12%; small patient cohort CL10 supports an increase. This did not prove a clinical arrhythmia or serotonin-syndrome effect. CL11: CBD 2.5 mg/kg twice daily for 12 days in the citalopram cohort; not a blanket seven-day duration.

Uncertainties and limitations

Do not present racemic citalopram findings as escitalopram results without identifying the distinction.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0031

Type of result: Positive finding / indication

Observation: Citalopram measurements increased in the combined sample.

Mechanism: CYP2C19/CYP3A4 inhibition plausible

Study type: Small clinical ancillary investigation

Context studied: Shared exploratory subgroup of six people (15–24 years) receiving citalopram or escitalopram from an open-label study of 31 people in total. CBD capsules (>99.9%) starting at 200 mg/day, all reaching 600 mg/day by week 4; three increased to 800 mg/day by week 8. Measurements at baseline and weeks 4, 8 and 12.

Clinical interpretation: Possible; increase in adverse effects unclear

Limitations and uncertainties: No separate robust effect estimate per medicine and not an AUC study. Samples at 8–10 a.m. with usual individual administration times, not established as standardised trough concentrations. Antidepressant adherence mainly self-reported. Internal contradiction in the original: Table 2/footnote lists five escitalopram and one citalopram participant, whereas a results sentence reverses the numbers; keep subgroup allocation unresolved.

Original sources for this finding: Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People [CL10]

CBD – clinically studied

Finding ID: B0033

Type of result: Positive finding / indication

Observation: Citalopram AUC∞ ratio 1.43 (90% CI 1.34–1.52), Cmax ratio 1.12 (1.06–1.17). This short-term pharmacokinetic study does not establish long-term clinical consequences.

Mechanism: Metabolic inhibition plausible

Study type: Open-label sequential human pharmacokinetics

Context studied: Healthy adults: 20 enrolled, pharmacokinetic analysis n=19 (one excluded for pre-existing citalopram exposure/protocol violation). Citalopram 20 mg on days 1 and 13; CBD solution 2.5 mg/kg twice daily (=5 mg/kg/day) on days 6–17, 12 days in total. Comparison on day 13 after seven days of CBD pretreatment, sampling up to 120 hours.

Clinical interpretation: Possible; clinical endpoints unclear

Limitations and uncertainties: No CYP2C19 poor metabolisers; healthy people.

Original sources for this finding: Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults [CL11]

References and access status

[CA_L_D0090] CITALOPRAM (CITALOPRAM HYDROBROMIDE) TABLET, FILM COATED [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: REMEDYREPACK INC.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL10] Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People

Original source / bibliographic reference

Authors: Anderson LL; Doohan PT; Oldfield L; Kevin RC; Arnold JC; Berger M; Amminger GP; McGregor IS

Year: 2021

Source type: In-vitro study plus a small accompanying clinical investigation

DOI: 10.1097/JCP.0000000000001427

PMID: 34121064

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CL11] Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults

Original source / bibliographic reference

Authors: Salcedo P; Volpe DA; Chaturbedi A; Shah A; Krishna A; Hyland PL; Vegesna G; Hsiao CH; De Palma R; Fein M; Rouse R; Florian J

Year: 2026

Source type: Open-label sequential human pharmacokinetic study

DOI: 10.1002/cpt.70219

PMID: 41622700

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility